# 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Source: https://onco.cc/trials/nct00450619/  
OnCo record `nct00450619` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Samarium-153 lexidronam and Sargramostim in Prostate cancer, run by National Cancer Institute (NCI), completed.

## Summary

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer is a phase 2 interventional study registered as NCT00450619 by National Cancer Institute (NCI), with 44 participants recorded, started 2007-02 and reaching its primary completion in 2012-11. Interventions recorded: Samarium Sm 153 lexidronam pentasodium, Sargramostim, Recombinant vaccinia-TRICOM vaccine, Recombinant fowlpox-TRICOM vaccine. Conditions recorded: Prostate Cancer.

Linked to the drug Samarium-153 lexidronam because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00450619
- Phase: 2
- Setting: A Randomized Phase 2.5 Study of (153)Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 44

## Sources

- ClinicalTrials.gov NCT00450619: https://clinicaltrials.gov/study/NCT00450619

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Samarium-153 lexidronam](https://onco.cc/drugs/samarium-153-lexidronam/), [Sargramostim](https://onco.cc/drugs/sargramostim/)

---
JSON: https://onco.cc/api/v1/entities/nct00450619.json